Nxera Pharma Appoints Shinya Tsuzuki To Strengthen Investor Relations Leadership In Japan

Nxera Pharma Co., Ltd. has appointed Shinya Tsuzuki as Head of Investor Relations. In his new role, Tsuzuki will be responsible for directing the company’s investor engagement strategy in Japan and will report directly to CFO Hironoshin Nomura. 

Hironoshin Nomura, CFO of Nxera, said, “I am delighted to welcome Mr. Tsuzuki to Nxera at this exciting time as we enter a new stage of growth. His deep understanding of the pharmaceutical and biotechnology sectors, combined with his well-established relationships across the investor community in Japan and internationally, will be a tremendous asset for us to foster interest in the Company, as well as the industry as a whole.” 

Tsuzuki brings extensive expertise in pharmaceutical and biotech equity research, having worked as a Senior Investment Analyst at Mizuho Securities since 2018. Over the years, he has consistently ranked among the top analysts in the Nikkei Veritas and Extel rankings, formerly Institutional Investor, securing second place in 2022 and 2023, and remaining in the top four through 2025.

Shinya Tsuzuki, Head of Investor Relations at Nxera, stated, “I am excited to join Nxera during this period of evolution to become a next-generation biopharma business. I look forward to strengthening our investor communications and relationships, both in Japan and internationally, and contributing to Nxera’s continued growth as it aims to become a leading biopharmaceutical company in Japan.”

He graduated from Nagoya University with a bachelor's and master's degree in engineering. Tsuzuki is anticipated to improve Nxera's engagement with the investment community and strengthen its position in the capital markets with his solid analytical background and industry knowledge.